T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).
Michael B. Atkins,Elizabeth R. Plimack,Igor Puzanov,Mayer Fishman,David F. McDermott,Daniel C. Cho,Ulka N. Vaishampayan,Saby George,Thomas Olencki,Jamal Tarazi,Brad Rosbrook,Kathrine C. Fernandez,Mariajose Lechuga,Toni K. Choueiri +13 more
TL;DR: This data indicates that pre-existing studies combining programmed death-1 checkpoint inhibitors with tyrosine kinase inhibitors of the vascular endothelial growth factor pathway have been characterIZed as positive for PD-1 checkpoints and VEGF checkpoint blockade is likely to be beneficial.
Journal ArticleDOI
Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.
David F. McDermott,Charles G. Drake,Mario Sznol,Toni K. Choueiri,John D. Powderly,David Smith,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Michael B. Atkins +9 more
TL;DR: BMS-936558 is tolerable and exhibits ongoing durable clinical activity in pts with previously treated mRCC and demonstrates nonconventional response patterns and was not categorized as responders by conventional RECIST.
Journal ArticleDOI
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium
Toni K. Choueiri,Chris Labaki,Ziad Bakouny,Chih-Yuan Hsu,Andrew Schmidt,G. de Lima Lopes,Clara Hwang,Sunny Singh,Chinmay Jani,Lisa Weissmann,Elizabeth A. Griffiths,Susan Halabi,Ulysses S. Wu,Stephanie Berg,Timothy E. O'Connor,Trisha Wise-Draper,Orestis A. Panagiotou,Elizabeth Klein,Monika Joshi,Fares Yared,Miriam S. Dutra,Na Tosha Gatson,Sibel Blau,Harpreet Singh,Rahul Nanchal,Rana R. McKay,Taylor K. Nonato,Ryann Quinn,Samuel M. Rubinstein,Matthew Puc,Blanche Mavromatis,Praveen Vikas,Bryan A. Faller,Howard Zaren,Salvatore Del Prete,Karen Russell,Daniel Y. Reuben,Melissa K. Accordino,Christopher R. Friese,Sanjay Mishra,Donna R. Rivera,Yu Shyr,Dimitrios Farmakiotis,Jeremy L. Warner +43 more
TL;DR: In this article , the clinical characteristics and outcomes of patients with cancer who developed breakthrough SARS-CoV-2 infections after 2 or 3 doses of mRNA vaccines were evaluated using a multivariable logistic regression model after inverse probability of treatment weighting to adjust for potential baseline confounding variables.
Journal ArticleDOI
Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial.
David Cella,Toni K. Choueiri,Steven I. Blum,Flavia Ejzykowicz,Melissa Hamilton,Joshua Zhang,Cristina Ivanescu,Robert J. Motzer +7 more
TL;DR: Patients with aRCC were randomized 1:1 (stratified by International Metastatic Renal Cell Carcinoma Database Consortiu... to select patients for CheckMate 9ER treatment.
Journal ArticleDOI
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors
Harish Seethapathy,Sarah Street,Ian A. Strohbehn,Meghan Lee,Sophia H. Zhao,Nifasha Rusibamayila,Donald F. Chute,Xin Gao,M.D. Michaelson,Osama E. Rahma,Toni K. Choueiri,Brad McGregor,Guru Sonpavde,Cristina Salabao,Marina D. Kaymakcalan,Xiao Wei,Shruti Gupta,Shveta S. Motwani,David E. Leaf,Kerry L. Reynolds,Meghan E. Sise +20 more
TL;DR: In this paper, the effect of immune checkpoint inhibitors (ICIs) on kidney function is unknown in patients with genitourinary cancers, and a retrospective cohort study of patients with renal cell carcinoma (RCC) and urothelial carcinoma who received ICIs at two major cancer centers between 2012 and 2018 was conducted.